Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01441947
What this trial is testing

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 68
Early research (Phase 1)Study completedNCT03544125
What this trial is testing

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor NegativeHER2/Neu Negative+3 more
OHSU Knight Cancer Institute 3
Testing effectiveness (Phase 2)Study completedNCT00933517
What this trial is testing

Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.

Who this might be right for
Pathological Response Rate
Centre Jean Perrin 62
Testing effectiveness (Phase 2)Study completedNCT05163106
What this trial is testing

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

Who this might be right for
Breast CancerHER2-negative Breast CancerER-positive Breast Cancer+3 more
University Hospital, Akershus 85
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Large-scale testing (Phase 3)Temporarily pausedNCT05503108
What this trial is testing

Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Who this might be right for
Fasting Mimicking DietHER2-negative Breast CancerHormone Receptor-positive Breast Cancer+3 more
Leiden University Medical Center 10
Not applicableActive Not RecruitingNCT05132790
What this trial is testing

Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Who this might be right for
Breast Cancer
Shengjing Hospital 24
Testing effectiveness (Phase 2)Ended earlyNCT05176080
What this trial is testing

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 46
Testing effectiveness (Phase 2)WithdrawnNCT01557764
What this trial is testing

Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine
Testing effectiveness (Phase 2)Ended earlyNCT01147016
What this trial is testing

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Who this might be right for
Breast Cancer
Barbara Ann Karmanos Cancer Institute 8
Not applicableLooking for participantsNCT07702708
What this trial is testing

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Breast CancerBreast Neoplasms
Fujian Cancer Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT04577963
What this trial is testing

Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Triple Negative Breast CancerEndometrial CancerSolid Tumor, Unspecified, Adult+1 more
Hutchmed 52
Large-scale testing (Phase 3)Looking for participantsNCT05879926
What this trial is testing

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Who this might be right for
Breast Cancer
NRG Oncology 3,960
Large-scale testing (Phase 3)Not Yet RecruitingNCT07340658
What this trial is testing

Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Rovi Pharmaceuticals Laboratories 300
Large-scale testing (Phase 3)Study completedNCT01619111
What this trial is testing

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Who this might be right for
HER2-negative Metastatic Breast CancerHER2-positive Circulating Tumor Cells
Prof. Wolfgang Janni 105
Post-approval studies (Phase 4)Study completedNCT00127933
What this trial is testing

XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 157
Large-scale testing (Phase 3)Study completedNCT00938652
What this trial is testing

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 519
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07109284
What this trial is testing

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

Who this might be right for
ER+HER2- Breast Cancer
West China Hospital 55
Testing effectiveness (Phase 2)Active Not RecruitingNCT05607004
What this trial is testing

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Who this might be right for
Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast Cancer+1 more
Atossa Therapeutics, Inc. 87
Next Page